Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
British Journal of Haematology|December 16, 2016
Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemiaTadeusz Robak, Andrzej Hellmann, Janusz Kloczko, et al.
Leukemia & Lymphoma|November 11, 2016
Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLLTadeusz Robak, Krzysztof Warzocha, K Govind Babu, et al.
The Lancet. Haematology|March 5, 2017
Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trialJeffrey A Jones, Tadeusz Robak, Jennifer R Brown, et al.
Pharmaceutical Research|May 3, 2019
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS TrialSilvia Maria Lavezzi, Jan de Jong, Martine Neyens, et al.
European Journal of Haematology|July 17, 2015
Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myelomaFrancisco Javier Peñalver, Julio Delgado, Javier Loscertales, et al.
Leukemia & Lymphoma|October 13, 2016
Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trialTadeusz Robak, Krzysztof Warzocha, K Govind Babu, et al.
Leukemia & Lymphoma|July 27, 2013
Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC)Montserrat López Rubio, Carolina Da Silva, Javier Loscertales, et al.
British Journal of Haematology|January 10, 2012
Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy resultsJulio Delgado, Blanca Espinet, Ana C Oliveira, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2010
Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemiaTadeusz Robak, Anna Dmoszynska, Philippe Solal-Céligny, et al.
Annals of Hematology|November 13, 2014
Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blastsPatricia Font, Javier Loscertales, Carlos Soto, et al.
Pageof 5